Antigen News and Research

RSS

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

Benefits of PSA screening for prostate cancer may outweigh potential harms

The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, according to a study published today in the New England Journal of Medicine.

22 Jun 2020

Balanced B and T cell response required to control SARS-CoV-2

A new study by researchers in the Netherlands and published on the preprint server bioRxiv in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19.

21 Jun 2020

Mutational targets of SARS-CoV-2 receptor-binding domain for vaccine-antiviral development

The COVID-19 pandemic has spread throughout the whole world within six months, causing millions of infections and hundreds of thousands of deaths. Yet there is no effective vaccine or antiviral to deal with it.

18 Jun 2020

Novel SARS-CoV-2 antibody cocktail impeccably mimics human antibody response

By using both humanized mice and convalescent patients, the researchers from the US and Singapore successfully generated non-competing and highly potent monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein that could potentially be combined to form antibody cocktails. Their groundbreaking paper is published in the leading research journal Science.

18 Jun 2020

Repurposing immunosuppressants to manage COVID-19

It might seem paradoxical to suggest immunosuppression could play a role in managing COVID-19. The seemingly logical therapeutic option for this disease would be an antiviral.

18 Jun 2020

Avacta provides update on Affimer therapy for COVID-19 infection

Avacta Group plc, is pleased to announce that collaborative work with the University of Glasgow has shown that Affimer reagents prevent infection.

From Avacta Life Sciences Ltd. 18 Jun 2020

COVID-19 and blood group in aortic valve replacement

The COVID-19 pandemic has been found to cause disproportionate harm in patients with cardiovascular disease, especially among the elderly population, among other risk factors. However, a new study published on the preprint server medRxiv* in June 2020 is the first to report its clinical features in patients with aortic stenosis who have had a transcatheter aortic valve replacement (TAVR).

18 Jun 2020

Researchers call for caution of using CAR-T immunotherapy against AML

Acute myeloid leukemia is a hematological malignancy which incidence increases with age, that is biologically, phenotypically, and genetically very heterogeneous.

17 Jun 2020

Celltrion announces plans to launch COVID-19 point-of-care antigen testing kit

Celltrion Group today announced plans to expand its diagnostic portfolio for SARS-CoV-2, the virus causing COVID-19, in its efforts to improve access to COVID-19 testing and help prevent the further spread of coronavirus infection worldwide.

17 Jun 2020

Relaxation time of T cells crucial to immune response

Like finding that needle in the haystack every time, your T cells manage what seems like an improbable task: quickly finding a few invaders among the many imposters in your body to trigger its immune response.

16 Jun 2020

UCLA receives nearly $14 million NIH grant to investigate immunotherapy to destroy HIV

UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.

16 Jun 2020

Study reports structure of enzyme activator for high pathogenic avian influenza

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the current pandemic of COVID-19, is the focus of many investigators seeking to find an effective vaccine or therapeutic. Among the potential targets are various protease enzymes suspected of allowing the virus to gain entry to host cells and establish a successful infection.

16 Jun 2020

JRC creates a database of COVID-19 diagnostic devices and test methods

As part of EU efforts to provide guidance on the use of coronavirus tests, the JRC has created a database of COVID-19 in vitro diagnostic devices and test methods that gathers information on available tests in one place.

12 Jun 2020

Damon Runyon Cancer Research Foundation awards $3.2 million to early-career physician-scientists

The Damon Runyon Cancer Research Foundation has named four new Damon Runyon Clinical Investigators.

12 Jun 2020

New, reliable tests identified for detecting antibodies specific to SARS-CoV-2

A new analysis of blood sera taken from 63 COVID-19 patients, 71 controls, and various coronavirus-exposed animals provides strong support for the use of the SARS-CoV-2 virus' receptor-binding domain (RBD) as an antigen for reliable tests to detect antibodies to the virus.

12 Jun 2020

Study reveals novel mechanism that triggers a cell-mediated immune response

Viruses and other disease-causing microbes influence the type of immune response their hosts will develop against them. In some cases, the predominant response involves antibodies, proteins made by the immune system that specifically recognize parts of the invading microbe and mediate its destruction.

11 Jun 2020

Turning autoimmunity drugs into anti-cancer treatments

Professor Mark Cragg speaks to News-Medical about his research which involves turning autoimmunity drugs into anti-cancer treatments.

11 Jun 2020

Hydroxychloroquine suppresses 'trained immunity'

A new study published on the preprint server medRxiv in June 2020 shows that the drug hydroxychloroquine (HCQ) suppresses a form of immunity called ‘trained immunity,’ with repercussions for its potential use to treat COVID-19.

11 Jun 2020

Seroprevalence of IgM and IgG against SARS-CoV-2 in China

A new study published in the journal Nature Medicine in June 2020 reports the seroprevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across China. This may help to understand the actual prevalence of the virus in the current pandemic.

10 Jun 2020